Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T13688 |
Eribulin
B1939,艾日布林,ER-086526,E7389 |
Others | Others |
Eribulin inhibits the proliferation of cancer cells by binding microtubule proteins and microtubules. Eribulin is a microtubule targeting agent that is used in the treatment of metastatic breast cancer. | |||
T13687 |
Eribulin mesylate
B1939 mesylate,甲磺酸艾日布林,ER-086526 mesylate,E7389 mesylate |
Apoptosis; Others; Microtubule Associated | Apoptosis; Cytoskeletal Signaling; Others |
Eribulin mesylate (E7389 mesylate) 是一种靶向微管的抗癌剂,通过结合微管蛋白和微管来抑制癌细胞的增殖,可研究转移性乳腺癌。 | |||
T39579 |
Mal-(CH2)5-Val-Cit-PAB-Eribulin
Mal-(CH2)5-Val-Cit-PAB-Eribulin |
||
Mal-(CH2)5-Val-Cit-PAB-Eribulin is a potent antitumor ADC drug-linker conjugate that utilizes Eribulin, an anti-microtubule agent, connected through the Mal-(CH2)5-Val-Cit-PAB linker. | |||
T18871 |
VCP-Eribulin
|
Others | Others |
VCP-Eribulin, an Eribulin-based drug for antibody conjugates[1], combines the VCP (ADCs linker) with Eribulin, a distinct microtubule inhibitor used in cancer treatments[2]. | |||
T18278 |
Mal-PEG2-VCP-Eribulin
|
Others | Others |
Mal-PEG2-VCP-Eribulin is a chemotherapeutic compound comprising an antibody-drug conjugate (ADC) linker (Mal-PEG2-VCP) and the microtubule inhibitor Eribulin[1]. This compound uniquely targets microtubules, offering a novel approach to cancer treatment. Eribulin is specifically utilized in creating targeted Eribulin-based drugs for antibody conjugates[1]. | |||
T82323 |
GGFG-Eribulin
|
||
GGFG-Eribulin(Compound GGFG)是一种用于合成ADCs的ADC-药物连接子偶联物。它由ADC细胞毒素Exatecan和连接子构成,以实现靶向输送药物。 | |||
T77908 |
Farletuzumab ecteribulin
MORAb-202 |
||
Farletuzumabecteribulin(MORAb-202)是一款人源化抗人叶酸受体α(FRA)抗体Farletuzumab与Mal-PEG2-Val-Cit-PAB-eribulin通过还原的链间二硫键偶联成的抗体-活性分子偶联物(ADC)。该化合物活性分子抗体比率为4.0,对FRA阳性细胞展示出强大的体外细胞毒性,并具备有效的抗肿瘤活性。 |